KNSA Kiniksa Pharmaceuticals
- 19.580
- +0.050+0.26%
- 19.580
- 0.0000.00%
Kiniksa Pharmaceuticals News
Market Underestimates Kiniksa Pharmaceuticals' Abiprubart Potential Despite Positive Industry Indicators
Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference
PDF Version HAMILTON, Bermuda, May 07, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Bank of A
Kiniksa Pharmaceuticals (KNSA.US) was covered for the first time by Wells Fargo, giving it an increase rating, with a target price of $34.00.
Kiniksa Pharmaceuticals (KNSA.US) was covered for the first time by Wells Fargo, giving it an increase rating, with a target price of $34.00.
Wells Fargo Initiates Coverage On Kiniksa Pharmaceuticals With Overweight Rating, Announces Price Target of $34
Wells Fargo analyst Eva Fortea Verdejo initiates coverage on Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight rating and announces Price Target of $34.
Kiniksa Pharmaceuticals Is Maintained at Overweight by JP Morgan
Kiniksa Pharmaceuticals Is Maintained at Overweight by JP Morgan
Komo: Maintaining the Kiniksa Pharmaceuticals (KNSA.US) rating, adjusted from an increase in holdings to an increase rating, and the target price was adjusted from $26.00 to $30.00.
Komo: Maintaining the Kiniksa Pharmaceuticals (KNSA.US) rating, adjusted from an increase in holdings to an increase rating, and the target price was adjusted from $26.00 to $30.00.
JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $30
JP Morgan analyst Anupam Rama maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $26 to $30.
Kiniksa Pharmaceuticals (NASDAQ:KNSA): New Drug Treatment Could Have Upside Potential
Kiniksa Pharmaceuticals Faces Capital Raising Hurdles Amid Stricter UK Shareholder Voting Laws
Analyst Estimates: Here's What Brokers Think Of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) After Its First-Quarter Report
Kiniksa Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group
Kiniksa Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group
Evercore ISI Group: Maintaining the Kiniksa Pharmaceuticals (KNSA.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $25.00 to $30.00.
Evercore ISI Group: Maintaining the Kiniksa Pharmaceuticals (KNSA.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $25.00 to $30.00.
Evercore ISI Group Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $30
Evercore ISI Group analyst Liisa Bayko maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperform and raises the price target from $25 to $30.
Kiniksa Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/24/2024 63.49% Evercore ISI Group $25 → $30 Maintains Outperform 01/02/2024 36.24% Wedbush $23 → $25 Ma
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q1 2024 Earnings Call Transcript
Buy Rating Affirmed for Kiniksa Pharmaceuticals Amid Strong Q1 Performance and Promising Drug Prospects
Earnings Call Summary | Kiniksa Pharmaceuticals(KNSA.US) Q1 2024 Earnings Conference
The following is a summary of the Kiniksa Pharmaceuticals Ltd. (KNSA) Q1 2024 Earnings Call Transcript:Financial Performance:Kiniksa Pharmaceuticals reported strong Q1 2024 results with an 85% year-ov
Buy Rating Affirmed for Kiniksa Pharmaceuticals Amidst Growth Potential and Strong Commercial Execution
Kiniksa Pharmaceuticals Ltd (KNSA) Q1 2024 Earnings Overview: Surpasses Revenue Forecasts
Kiniksa Expects 2024 Arcalyst Net Product Revenue Of $370M-$390M Compared To Prior Guidance Of $360M-$380M
Kiniksa Expects 2024 Arcalyst Net Product Revenue Of $370M-$390M Compared To Prior Guidance Of $360M-$380M
Analysis
Price Target
No Data
